Navigation Links
Lilly Reports First-Quarter 2013 Results
Date:4/24/2013

arch and development1,348.11,151.5

17%Marketing, selling and administrative1,652.01,847.5

(11)%Operating income 1,443.61,405.1

3%Net interest income (expense)(16.7)(19.2)Net other income (expense)50.5(26.8)Other income  (expense)33.8(46.0)

NMIncome before income taxes1,477.41,359.1

9%Income taxes229.7332.2

(31)%Net income

$

1,247.7

$

1,026.9

22%Earnings per share – diluted

$

1.14

$

0.92

24%Dividends paid per share

$

0.49

$

0.49

0% 

Weighted-average sharesoutstanding (thousands) – diluted 

 

1,091,876 

 

1,116,983(a) The first-quarter 2013 financial statements have been adjusted to eliminate asset impairments, restructuring and other special charges totaling $21.7 million (pretax), or $0.01 per share (after-tax), related to severance costs from actions the company is taking, primarily outside the U.S., to reduce its cost structure and global workforce. Additionally, they have been adjusted to eliminate income totaling $495.4 million (pretax), or $0.29 per share (after-tax), related to the transfer of exenatide commercial rights outside the U.S. to Amylin.

(b) The first-quarter 2012 financial statements have been adjusted to eliminate asset impairments, restructuring and other special charges totaling $23.8 million (pretax), or $0.01 per share (after-tax), primarily related to the withdrawal of Xigris.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

Refer to: (317) 276-5795 – Mark Taylor (Media)
(317) 655-6874 – Philip Johnson (Investors)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. DiversityInc Names Lilly a Top Company for Diversity
2. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
3. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
4. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
5. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
9. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
10. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
11. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015 /PRNewswire/ ... a three-dimensional biology company focused on delivering scientific ... announced that the Company has hired Paul ... in vitro tissue service and product business. Mr. Gallant ... R&D experience in the drug discovery industry, most ...
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015  Mirati Therapeutics, ... focusing on genetic and epigenetic drivers of cancer, will be ... August 11, 2015 at 1:55 p.m. ET (10:55 a.m. PT) ... Baum , M.D., Ph.D., president and CEO of Mirati, will ... of the presentation will be accessible on the "Investors" page ...
(Date:8/3/2015)... 2015   The Intellectual Property and Science ... provider of intelligent information for businesses and professionals ... Pharmaceutical R&D Factbook , the biopharmaceutical industry,s leading ... declines in R&D, the analysis identifies a surge ... and forecasts sales to reach $1.3 trillion by ...
Breaking Medicine Technology:Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3Pharma Sales to Grow Beyond $1 Trillion 2
... June 21, 2010 ReportsandReports announces it Will,Carry Cardiovascular Devices Market ... , , ... http://www.reportsandreports.com/market-reports/netherlands-cardiovascular-de ,vices-market-outlook-to-2016/) , , , ... (Due to the length of these URLs, it may be necessary to copy ...
... AHMEDABAD, India , June 21, 2010 ... healthcare companies has,received Phase I clinical trial permission from the DCGI for ... Centre using a,unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule. ... ...
Cached Medicine Technology:Cardiovascular Devices Market Outlook June Update by ReportsandReports 2Cardiovascular Devices Market Outlook June Update by ReportsandReports 3Cardiovascular Devices Market Outlook June Update by ReportsandReports 4Cardiovascular Devices Market Outlook June Update by ReportsandReports 5Cardiovascular Devices Market Outlook June Update by ReportsandReports 6Cardiovascular Devices Market Outlook June Update by ReportsandReports 7Cardiovascular Devices Market Outlook June Update by ReportsandReports 8Cardiovascular Devices Market Outlook June Update by ReportsandReports 9Cardiovascular Devices Market Outlook June Update by ReportsandReports 10Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial 2Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial 3
(Date:8/4/2015)... ... 04, 2015 , ... Increasingly, patients are researching online to ... In an effort to share more and better information with these savvy and ... share patient satisfaction ratings and comments about its doctors and advanced practice providers. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Mesothelioma researchers ... come back: Retreatment may be a viable option. Surviving Mesothelioma has just posted ... , According to surgeons at the University of New South Wales, peritoneal ...
(Date:8/4/2015)... ... August 04, 2015 , ... Sin ... unique artistic expressions from a diverse group of exceptionally talented female artists. ... & Art Festival on September 25-27, 2015 in Downtown Las Vegas. Curated by ...
(Date:8/4/2015)... New York, NY (PRWEB) , ... August 04, ... ... FHA multifamily mortgage lender specializing in healthcare finance, announced the closing of a ... operates a two campus health system located in Smithfield and Clayton, North Carolina. ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... The ... designed to treat Retinitis pigmentosa, a rare eye disease that progressively causes blindness, were ... Academy of Ophthalmology. According to the results of the trial, the implant, more commonly ...
Breaking Medicine News(10 mins):Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2
... , NEW YORK, Nov. 18 WAT,s-THE-WORD?! is the first ... products, discoveries on the web and real-life experiences from a ... boys who helped their parents conceive the brand WAT-AAH! ... mom a "cooler" and better name for water, thus WAT-AAH!. ...
... 18 Banfield, The Pet Hospital® today announced ... its medical specialist/nutritionist. With nearly 20 years experience in veterinary ... platform that will position Banfield as a leader in veterinary ... as part of the Medical Quality Advancement team at Banfield,s ...
... , WASHINGTON, Nov. 18 The Union Labor ... subsidiary of ULLICO Inc., a privately held financial and ... provide pharmacy benefit management services to labor group clients. ... union employers and their members with a comprehensive pharmacy ...
... Institutet have discovered that patients with recent-onset schizophrenia have ... findings offer hope of being able to treat schizophrenia ... The causes of schizophrenia are largely unknown, and this ... that infections caught early on in life might increase ...
... have shown that lipid peroxidation stimulates collagen production ... plays an important role in the development of ... carbon tetrachloride, cholestasis and alcohol induced liver fibrosis ... effect of green tea in dimethylnitrosamine (DMN)-induced models ...
... stall carotid artery disease , WEDNESDAY, Nov. 18 (HealthDay ... additional benefit to seniors with coronary artery disease who ... , The 18-month study of 145 Baltimore-area men and ... arterial wall thickness reductions between those who took 1,500 ...
Cached Medicine News:Health News:WAT-AAH!, The First Functional Bottled Water For Kids, Announces The Release of WAT's-THE-WORD?! 2Health News:Banfield, The Pet Hospital(R) Welcomes Board Certified Nutritionist, Medical Specialist to Practice 2Health News:Banfield, The Pet Hospital(R) Welcomes Board Certified Nutritionist, Medical Specialist to Practice 3Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 2Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 3Health News:Immune system activated in schizophrenia 2Health News:Niacin Adds No Benefit for Statin Patients: Study 2
... The Ray TFC Unite Device is the ... The Ray TFC Unite device features the same ... contact offered by fenestrations is paramount in the ... the Ray TFC Unite system promotes load sharing ...
... The INTER FIX and ... Devices are designed to maximize ... of the implant. Both the ... RP Threaded Fusion devices combine ...
... Confirmatory (Western Blot): The Genetic Systems HIV-1 ... for the detection of antibodies to HIV-1. The ... of HIV-1 grown in the CEM cell line. ... devoid of HLA Class ll antigens, helps reduce ...
Prognosis / Patient Management. HIV-1 Viral Load Assay. NucliSens HIV-1 QT covers the entire dynamic range of viral load testing from a single patient sample, without reflex testing or thermalcycli...
Medicine Products: